- Home
- MBRX vs IBG Comparison
MBRX vs IBG Comparison
Compare MBRX & IBG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MBRX | IBG |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Beverages (Production/Distribution) |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.6M | 8.8M |
| IPO Year | 2016 | 2024 |
Fundamental Metrics
Financial Performance| Metric | MBRX | IBG |
|---|---|---|
| Price | $3.79 | $2.19 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $105.50 | N/A |
| AVG Volume (30 Days) | ★ 608.5K | 116.8K |
| Earning Date | 11-13-2025 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,931,243.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.63 | $1.48 |
| 52 Week High | $91.25 | $9.85 |
Technical Indicators
Market Signals| Indicator | MBRX | IBG |
|---|---|---|
| Relative Strength Index (RSI) | 49.59 | 42.74 |
| Support Level | $3.74 | $2.15 |
| Resistance Level | $4.24 | $2.44 |
| Average True Range (ATR) | 0.52 | 0.19 |
| MACD | -0.32 | -0.01 |
| Stochastic Oscillator | 2.33 | 37.23 |
Price Performance
Historical ComparisonAbout MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
About IBG Innovation Beverage Group Limited Ordinary Shares
Innovation Beverage Group Ltd is a developer, manufacturer, marketer, exporter, and retailer of a growing beverage portfolio of 70 formulations across 14 alcoholic and non-alcoholic brands. The company's focus is on premium and super premium brands. The Group has two reportable geographic segments: Australia and the United States.